265 related articles for article (PubMed ID: 10596866)
1. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema.
Blais C; Rouleau JL; Brown NJ; Lepage Y; Spence D; Munoz C; Friborg J; Geadah D; Gervais N; Adam A
Immunopharmacology; 1999 Sep; 43(2-3):293-302. PubMed ID: 10596866
[TBL] [Abstract][Full Text] [Related]
2. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P.
Blais C; Marc-Aurèle J; Simmons WH; Loute G; Thibault P; Skidgel RA; Adam A
Peptides; 1999; 20(4):421-30. PubMed ID: 10458510
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin.
Molinaro G; Cugno M; Perez M; Lepage Y; Gervais N; Agostoni A; Adam A
J Pharmacol Exp Ther; 2002 Oct; 303(1):232-7. PubMed ID: 12235256
[TBL] [Abstract][Full Text] [Related]
4. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat.
Décarie A; Raymond P; Gervais N; Couture R; Adam A
Am J Physiol; 1996 Oct; 271(4 Pt 2):H1340-7. PubMed ID: 8897926
[TBL] [Abstract][Full Text] [Related]
5. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study.
Cyr M; Hume HA; Champagne M; Sweeney JD; Blais C; Gervais N; Adam A
Transfusion; 1999 Oct; 39(10):1084-8. PubMed ID: 10532602
[TBL] [Abstract][Full Text] [Related]
6. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.
Blais C; Drapeau G; Raymond P; Lamontagne D; Gervais N; Venneman I; Adam A
Am J Physiol; 1997 Nov; 273(5):H2263-71. PubMed ID: 9374762
[TBL] [Abstract][Full Text] [Related]
7. Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors.
Davin L; Marechal P; Lancellotti P; Martinez C; Pierard L; Radermecker R
Acta Cardiol; 2019 Aug; 74(4):277-281. PubMed ID: 30328786
[TBL] [Abstract][Full Text] [Related]
8. Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation.
Raymond P; Drapeau G; Raut R; Audet R; Marceau F; Ong H; Adam A
J Immunol Methods; 1995 Mar; 180(2):247-57. PubMed ID: 7714339
[TBL] [Abstract][Full Text] [Related]
9. Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema.
Decarie A; Adam A; Couture R
Peptides; 1996; 17(6):1009-15. PubMed ID: 8899821
[TBL] [Abstract][Full Text] [Related]
10. Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart.
Lamontagne D; Nadeau R; Adam A
Br J Pharmacol; 1995 Jun; 115(3):476-8. PubMed ID: 7582459
[TBL] [Abstract][Full Text] [Related]
11. Bradykinin B1 receptors in the rabbit urinary bladder: induction of responses, smooth muscle contraction, and phosphatidylinositol hydrolysis.
Butt SK; Dawson LG; Hall JM
Br J Pharmacol; 1995 Feb; 114(3):612-7. PubMed ID: 7735687
[TBL] [Abstract][Full Text] [Related]
12. Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation.
Molinaro G; Adam A; Lepage Y; Hammerschmidt D; Koenigbauer U; Eastlund T
Transfusion; 2002 Nov; 42(11):1458-65. PubMed ID: 12421219
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of bradykinin analogs by angiotensin I converting enzyme and carboxypeptidase N.
Drapeau G; Chow A; Ward PE
Peptides; 1991; 12(3):631-8. PubMed ID: 1656406
[TBL] [Abstract][Full Text] [Related]
14. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins.
Drapeau G; deBlois D; Marceau F
J Pharmacol Exp Ther; 1991 Dec; 259(3):997-1003. PubMed ID: 1662280
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies.
Aygören-Pürsün E; Magerl M; Maetzel A; Maurer M
Orphanet J Rare Dis; 2018 May; 13(1):73. PubMed ID: 29728119
[TBL] [Abstract][Full Text] [Related]
16. ACE inhibitor-mediated angioedema.
Montinaro V; Cicardi M
Int Immunopharmacol; 2020 Jan; 78():106081. PubMed ID: 31835086
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the receptor and the mechanisms underlying the inflammatory response induced by des-Arg9-BK in mouse pleurisy.
Vianna RM; Calixto JB
Br J Pharmacol; 1998 Jan; 123(2):281-91. PubMed ID: 9489617
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus.
Mathey CM; Maj C; Eriksson N; Krebs K; Westmeier J; David FS; Koromina M; Scheer AB; Szabo N; Wedi B; Wieczorek D; Amann PM; Löffler H; Koch L; Schöffl C; Dickel H; Ganjuur N; Hornung T; Buhl T; Greve J; Wurpts G; Aygören-Pürsün E; Steffens M; Herms S; Heilmann-Heimbach S; Hoffmann P; Schmidt B; Mavarani L; Andresen T; Sørensen SB; Andersen V; Vogel U; Landén M; Bulik CM; ; ; Bygum A; Magnusson PKE; von Buchwald C; Hallberg P; Rye Ostrowski S; Sørensen E; Pedersen OB; Ullum H; Erikstrup C; Bundgaard H; Milani L; Rasmussen ER; Wadelius M; Ghouse J; Sachs B; Nöthen MM; Forstner AJ
J Allergy Clin Immunol; 2024 Apr; 153(4):1073-1082. PubMed ID: 38300190
[TBL] [Abstract][Full Text] [Related]
19. Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins.
Drapeau G; Audet R; Levesque L; Godin D; Marceau F
J Pharmacol Exp Ther; 1993 Jul; 266(1):192-9. PubMed ID: 8392550
[TBL] [Abstract][Full Text] [Related]
20. Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.
Bélichard P; Loillier B; Paquet JL; Luccarini JM; Pruneau D
Br J Pharmacol; 1996 Apr; 117(7):1565-71. PubMed ID: 8730755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
